Full Press Release Details
YS Biopharma Announces Purchase of Shares by Company
GAITHERSBURG, Md., Aug. 24, 2023 /PRNewswire/ -- YS
Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and
cancer, today announced that the Company's Founder and Chairperson, Mr. Yi Zhang, and its Director and Chief Executive Officer,
Dr. Hui Shao, have purchased 429,188 of the Company's ordinary shares at an average price of $1.407 per share, and 46,300 of the
Company's ordinary shares at an average price of $1.46 per share, respectively, on the open market.
The investments by Mr. Yi Zhang and Dr. Hui Shao represent
their strong belief in YS Biopharma's long-term business strategy and growth potential. The purchases also reflect their confidence in
YS Biopharma's vision, mission, and commitment to delivering shareholder value. Both Mr. Yi Zhang and Dr. Hui Shao may purchase additional
shares through open market transactions or other authorized transaction methods in the future. The timing of such additional purchases
will depend on market conditions and be subject to regulatory requirements.
Dr. Hui Shao, Director, President, and CEO of YS Biopharma,
commented, "I have always believed in the unparalleled potential of YS Biopharma. At present, I believe the Company's current
stock price does not accurately reflect the significant intrinsic value of the Company. This investment is not just a financial decision,
but a testament to my faith in our team, our innovative products, and the future trajectory we envision. I am committed to YS Biopharma's
mission and am excited about what the future holds for us."
YS Biopharma is a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for
infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new
generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections.
YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management
team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking
statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of
1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current
fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth
of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma's ability
to source and retain talent, and the cash position of YS Biopharma following the closing of the Business Combination. Forward-looking
statements may be identified by the use of words such as "estimate," "plan," "project," "forecast,"
"intend," "will," "expect," "anticipate," "believe," "seek," "target"
or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These
statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's
management and are not predictions of actual performance.
These statements involve risks, uncertainties
and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those
expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking
statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors
currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described
in the final prospectus relating to the proposed Business Combination, and other documents filed by YS Biopharma from time to time with
the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking statements.
YS Biopharma cannot assure you that
the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number
of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs
related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations
as a result of the consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings, the
sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma,
and other risks and uncertainties, including those included in YS Biopharma's filings with the SEC. There may be additional
risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results
to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements,
nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements
in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may
cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current
intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements
as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law,
YS Biopharma does not undertake any duty to update these forward-looking statements.
Investor Relations Contacts
Director of Investor Relations
Email: ir@yishengbio.com
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com